Alex Zisson

Alex Zisson is a Partner at Thomas, McNerney & Partners. Alex joined the firm in 2002 and is currently a board member of Clarus Therapeutics, Inc. and Tranzyme Pharma, Inc. Before joining the firm, he spent 11 years in the research department at Hambrecht & Quist, and its successor firms, Chase H&Q and JPMorgan H&Q. During his tenure at H&Q, Mr. Zisson led research teams covering the biotechnology, specialty pharmaceutical, large-cap pharmaceutical, drug delivery and diagnostic industries. He was the lead analyst on 10 book-running IPOs and 20 book-run secondary offerings, raising over two billion for healthcare companies. In 1997, Mr. Zisson was named Managing Director and began assuming management responsibilities for the health care research group and the firm’s annual January conference. After the merger of Chase H&Q and JPMorgan, he became the firm’s Health Care Strategist. Mr. Zisson was named twice in The Wall Street Journal All-Star Analysts Survey, including during his last year at JPMorgan when he placed in all three categories: stock picking (#1 in pharmaceuticals), earnings estimate accuracy (tied for #2), and ‘home run’ hitting (#8 across all industries). He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.